Day: January 6, 2026

PMGC Holdings Inc. Announces Strategic Share Acquisition in Micro Modular Reactor (MMR) Focused Nuclear Energy Company, Nuclea Energy Inc.

Written by Customer Service on January 6, 2026. Posted in Mergers And Acquisitions.

The U.S. small and micro modular reactor (SMR/MMR) market is experiencing rapid growth, driven by energy security needs, data center demand, and federal support for advanced nuclear technologiesNEWPORT BEACH, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”), a diversified public holding company with multiple operating subsidiaries announces its investment arm PMGC Capital LLC. (“PMGC Capital”), has invested and acquired non-controlling shares in Nuclea Energy Inc. (“Nuclea Energy”), a company focused on the development and advancement of Micro Modular Reactor (MMR) and advanced nuclear energy solutions. The investment closed on November 6, 2025. The investment reflects PMGC Capital strategic focus on identifying and supporting companies positioned within long-term secular growth...

Edible Garden Preliminary Holiday Sales Surge 26.4% Year-Over-Year During Key Time Period

Written by Customer Service on January 6, 2026. Posted in Earnings Releases And Operating Results.

Strong Execution, Increased Velocity, Expanded Distribution and Industry-Leading Fulfillment Drives Results BELVIDERE, NJ, Jan. 06, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce and products, today announced a 26.4% year-over-year increase in preliminary sales during the Company’s key holiday selling period1 in 2025. Sales growth was broad-based across the Company’s core product portfolio. Cut and potted herbs delivered strong year-over-year gains, increasing approximately 26.7% and 25.0%, respectively. Hydroponic basil also posted solid growth of approximately 16.4%, while wheatgrass sales nearly doubled compared to the prior-year period. Condiments...

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

Written by Customer Service on January 6, 2026. Posted in Public Companies.

Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the Company’s TULSA-PRO® system. The milestone marks the official launch of TULSA-PRO at one of the world’s most influential centers for prostate cancer innovation and coincides with the opening of Johns Hopkins Medicine’s new interventional MRI (“iMRI”) suite — signaling the continued evolution of MRI from...

Archrock Announces Private Offering of $500 Million of Senior Notes

Written by Customer Service on January 6, 2026. Posted in Public Companies.

HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — Archrock, Inc. (NYSE: AROC) (“Archrock”) today announced that Archrock Services, L.P. (“Archrock Services”), a wholly-owned subsidiary of Archrock, intends, subject to market and other conditions, to offer and sell to eligible purchasers $500 million aggregate principal amount of senior notes due 2034 (the “Notes”). Archrock Partners Finance Corp., a wholly-owned subsidiary of Archrock Partners, L.P., will serve as co-issuer of the Notes. Archrock intends to use the net proceeds from the offering of the Notes to repay a portion of the outstanding borrowings under Archrock’s revolving credit facility. The Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and, unless so registered, may not be offered or sold in...

Rail Vision Advances Indian Market Entry with Demonstration for Senior Governmental Officials from Multiple Government Departments

Written by Customer Service on January 6, 2026. Posted in Public Companies.

Ra’anana, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, today announced a significant expansion of its activities in India, following the recent commencement of a Proof of Concept (POC) for multiple government officials and senior key players of the Indian Railway industry. During the POC, Rail Vision will demonstrate its Mainline product capabilities in challenging local operating conditions, representing an important step toward potential large-scale adoption. Indian Railways is one of the world’s largest networks by size as of 2024, with a total route length of 69,181 km as of 31 March 2024. It carried 6.905 billion passengers annually in the 2023–24 fiscal...

Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference

Written by Customer Service on January 6, 2026. Posted in Public Companies.

•New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) •Company to outline integration as a wholly owned subsidiary into Biocon Ltd., strengthening its global leadership in biosimilar insulins and GLP 1 peptide generics to cover the full spectrum of diabetes care BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) — Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited...

EVTV Executes Transformational AZIO AI Acquisition Framework at $3.00 Per Share

Written by Customer Service on January 6, 2026. Posted in Mergers And Acquisitions.

EVTV Board of Directors Approves Amended and Restated LOI with AZIO AI at $3.00 Per Share, Subject to Independent Third-Party Valuation HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — via IBN — Envirotech Vehicles, Inc. (NASDAQ:EVTV) (“EVTV” or the “Company”) today announced that it has entered into an Amended and Restated Letter of Intent (“LOI”) with AZIO AI Corporation (“AZIO AI”), pursuant to which EVTV would acquire 100% of the issued and outstanding equity interests of AZIO AI through a merger transaction. The LOI reflects preliminary understandings only and does not create any obligation on behalf of either party with respect to the contemplated transaction, except with respect to customary exclusivity, no-shop, confidentiality and expense provisions. The contemplated transaction...

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Written by Customer Service on January 6, 2026. Posted in Public Companies.

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerabilityAbsence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizuresREM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep duration Company has initiated preparations for global registrational trials in both DEE and Absence Seizure patients Bright Minds to hold conference call and live webcast at 8AM ET todayNEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today...

Alvotech announces planned CEO succession and leadership transition

Written by Customer Service on January 6, 2026. Posted in Public Companies.

Photo of Lisa GraverLisa Graver, Incoming CEO of AlvotechRóbert Wessman to continue serving as Executive Chairman in full-time capacity Lisa Graver appointed Chief Executive OfficerREYKJAVIK, ICELAND (January 6, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company’s inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capacity. Lisa Graver has been appointed as his successor as Chief Executive Officer. “When I stepped into...

Alvotech announces planned CEO succession and leadership transition

Written by Customer Service on January 6, 2026. Posted in Public Companies.

Photo of Lisa GraverLisa Graver, incoming CEO of Alvotech – Róbert Wessman to continue serving as Executive Chairman in full-time capacity – Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company’s inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capacity. Lisa Graver has been appointed as his successor as Chief Executive...

Day: January 6, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals